What the FDA labels say about taking them together
Adenosine and nelarabine
Nelarabine's FDA label of March 31, 2025 names adenosine in its drug interactions section; the adenosine label PlainMeds reads does not name nelarabine. The nelarabine label: “DRUG INTERACTIONS Administration of ARRANON in combination with adenosine deaminase (ADA) inhibitors, such as pentostatin, is not recommended.”
Check it at the source: the adenosine FDA label on DailyMed (effective April 14, 2025, Meitheal Pharmaceuticals Inc.); the nelarabine FDA label on DailyMed (effective March 31, 2025, Sandoz Inc).
What does the adenosine label say about nelarabine?
Adenosine's label (effective April 14, 2025) does not name nelarabine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Adenosine), Meitheal Pharmaceuticals Inc., effective April 14, 2025 (SPL set b6851256-6cef-4f23-8129-19bb64380cd5), via openFDA; the full label on DailyMed
What does the nelarabine label say about adenosine?
Nelarabine label, drug interactionsDRUG INTERACTIONS Administration of ARRANON in combination with adenosine deaminase (ADA) inhibitors, such as pentostatin, is not recommended [see Clinical Pharmacology (12.3)].
Source: FDA drug label (Arranon), Sandoz Inc, effective March 31, 2025 (SPL set 0f9051de-5c4d-4c0f-8c19-e15214498cca), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adenosine | Nelarabine | |
|---|---|---|
| Labeled for | n/a | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once